Telomir Pharmaceuticals (TELO)
Develops an oral small-molecule candidate for advanced triple-negative breast cancer.
$1.13
At close+0.03 (+2.73%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 2 | 1 | 6 | 3 | 2 | 5 | 1 | 2 | 1 | 2 | |
| Research & development | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| 1 | 0 | 1 | 1 | 5 | 3 | 2 | 5 | 0 | 1 | 1 | 1 | |
| Selling & marketing | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 1 | 1 | 5 | 3 | 2 | 5 | 0 | 1 | 1 | 1 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −1 | −1 | −2 | −1 | −6 | −3 | −2 | −5 | −1 | −2 | −1 | −2 |
| −1 | −8 | −4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 7 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −2 | −9 | −6 | −1 | −6 | −3 | −2 | −5 | −1 | −2 | −1 | −2 |
| Net income from continuing operations | −2 | −9 | −6 | −1 | −6 | −3 | −2 | −5 | −1 | −2 | −1 | −2 |
| Net income | −2 | −9 | −6 | −1 | −6 | −3 | −2 | −5 | −1 | −2 | −1 | −2 |
| EPS, basic | −$0.06 | −$0.32 | −$0.23 | −$0.05 | −$0.20 | −$0.10 | −$0.07 | −$0.17 | −$0.03 | −$0.06 | −$0.03 | −$1.39 |
| EPS, diluted | −$0.06 | −$0.32 | −$0.23 | −$0.05 | −$0.20 | −$0.10 | −$0.07 | −$0.17 | −$0.03 | −$0.06 | −$0.03 | −$1.39 |
| Weighted average shares, basic | 30 | 30 | 29 | 30 | 30 | 30 | 30 | 30 | 31 | 34 | 34 | 34 |
| Weighted average shares, diluted | 30 | 30 | 29 | 30 | 30 | 30 | 30 | 30 | 31 | 34 | 34 | 34 |
| EBITDA | −1 | −9 | 0 | −1 | −6 | −3 | −2 | −5 | −1 | −2 | −1 | −2 |
| Depreciation & amortization | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −9 | −2 | −1 | −6 | −3 | −2 | −5 | −1 | −2 | −1 | −2 |